Advertisements
Ezetimibe / Ezetimide / ZETIA Pharmaceutical Raw Materials for Hyperlipidemia , CAS 163222-33-1
Price: | US$ 1 / Gram |
---|---|
Minimum Order: | 10g |
Payment Terms: | TT, Western Union, moneygram |
Port of Export: | shanghai |
Product Details
Model No.: | Brand Name: | DMK |
---|
Certification: | SGS, ISO9001 |
---|---|
Specification: |
Certification : ISO9001 Place of Origin : China MOQ : 10g Price : negative Payment Terms : T/T, Western Union, MoneyGram, Supply Ability : 10000 kg per month Delivery Time : 2-3 working days Packaging Details : 1kg/Aluminum foil bag Synonyms : ZETIA CAS : C24H21F2NO3 MW : 409.43 Purity : 99% Package : 1kg/bag MF : C24H21F2NO3 |
Packaging & Delivery
Packaging: | aluminum foil |
---|---|
Delivery/Lead Time: | 3-7 working days |
Production Capacity: | 5000kg/M |
Product Description
Description: Ezetimibe is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the small intestine. It may be used alone (marketed as Zetia or Ezetrol), when other cholesterol-lowering medications are not tolerated, or together with statins (e.g., ezetimibe/simvastatin, marketed as Vytorin and Inegy) when statins alone do not control cholesterol.
Ezetimibe is recommended as second line therapy for those intolerant of statins or unable to achieve target LDL cholesterol levels on statins alone by several major medical group practice guidelines, but not by those of the American Heart Association and American College of Cardiology.
Medical uses:
While ezetimibe reduces LDL cholesterol, it has not been shown to have an impact on outcomes such as risk of death or major cardiovascular event like heart attack or stroke. Its effectiveness in reducing atherosclerosis in clinical trials has been inconsistent. The question of whether ezetimibe could make a difference in major outcomes was examined in the IMPROVE-IT trial, which compared treatment with ezetimibe vs. placebo on top of a background regimen of statin therapy in people who have had recent episodes of acute coronary syndrome over a six-year period. The trial results showing that ezetimibe treatment lowered the risk of experiencing a vascular event by 2%.
SUPPLIER PROFILE
|
|||
---|---|---|---|
Company: | Wuhan Demeikai Biotechnology Co., Ltd | ||
City/State | Wuhan, | Country: | China |
Business Type: | Export - Manufacturer / Trading Company | Established: | 2016 |
Member Since: | 2017 | Contact Person | Sam Wang, Miguel Jones, Icemile Cheng |
SUPPLIER PROFILE
City/State/Country -
Wuhan,
China
Business Type -
Export - Manufacturer / Trading Company
Established -
2016
Member Since -
2017
Contact Person -
Sam Wang, Miguel Jones, Icemile Cheng